Txomin Lalanne, Co-Founder and President
The preclinical research involved in central nervous system (CNS)-related pharmaceutical development tends to be the longest, most expensive, and least successful of all. One reason for this is the high rate of failure while translating the data results from preclinical animal studies to human clinical studies. Besides, owing to the difference in cell types among humans and animals, some compounds do not act the same way and show a significant behavioural difference in both tissues. Amid such disparities, electrophysiology seems to be a reliable approach for CRO service providers to foster successful CNS preclinical studies for clients. And, who can exemplify this better than the Bordeaux-based EphyX Neuroscience, a company bringing in-depth expertise in neurobiology and electrophysiology. EphyX Neuroscience is leading the charge in the market to deliver the best preclinical research results for pharma companies in terms of data quality, speed of acquisition, and scientific exchange.
“EphyX applies the technique of electrophysiology to induced pluripotent stem cells (iPSC) to help clients drastically limit the rate of failure in CNS-related early preclinical studies and drug discovery,” states Txomin Lalanne, the president and co-founder at EphyX Neuroscience.
EphyX Neuroscience has the expertise, equipment, and specialised facilities that enable it to deliver reliable neuroscience research services. This empowers clients to harness the highest quality of electrophysiological measurements in both rodent acute slices/dissociated cultures and human iPSC-derived neuronal cultures. EphyX Neuroscience hones the capability to test the effects on neuronal electrical activity and potential defensive mechanisms of various compounds, from single cells to network of cells and tissues. “We can provide a clear and detailed picture of the effects of various compounds on neuronal physiology, from brain circuits to single ion channels.
EphyX employs electrophysiology in induced pluripotent stem cells (iPSC) to help clients drastically limit the failure rate in neuroscience-related early preclinical studies
Also, by capturing data from human cells at preclinical stages, clients can optimise the selection of compounds to limit the risk of failures drastically,” explains Lalanne.
EphyX Neuroscience’s specialisation in CNS-related preclinical research helps it to undertake data recordings on specific transgenic animal and human models and employ acute or chronic compound exposition. On the flipside, clients are equipped with the ability to identify components that act positively on rodent models while showing different results in human neuronal cultures, thereby enabling them to generate predictive and useful information. This, in turn, goes a long way in guiding them to select the right compound, which gives positive results in both human iPSC-derived culture as well as rodent tissues, empowering clients to tread confidently into the next stages of their research programs.
EphyX Neuroscience offers its services in pre-designed packages that include modules addressing critical aspects of specific conditions as well as on-demand services to resolve specific requirements of clients and to assess mechanistic details about actions of their compounds. Apart from offering advanced preclinical studies and pharmaceutical development services, the company also develops its own pharmaceutical compounds through electrophysiology and collaborations. “Our perfect blend with an innovative on-site platform that offers key in vivo data, coupled with our in vitro specialisation offers a unique opportunity for pharmaceutical firms to boost their neuroscience-related preclinical research,” adds Lalanne.
With a broad clientele spanning prominent pharmaceutical companies in the US, Europe, and Japan, EphyX Neuroscience further plans to expand its geographical footprint and open an office in North America, which is a major marketplace for CROs. Besides, the company also looks forward to forming collaborations with other firms to boost the R&D activities of its preclinical studies and pharmaceutical compounds for moving ahead to the next phase of development.